Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jeffrey A MeyerhardtCharles S Fuchs

Abstract

To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer. Patients were eligible if they had metastatic colorectal cancer that progressed, were intolerant to first-line chemotherapy, or had disease recurrence within 1 year of adjuvant therapy for early-stage disease. Each 21-day cycle consisted of daily oral erlotinib at 150 mg, oral capecitabine at 1,000 mg/m2 (reduced to 750 mg/m2 after the first 13 patients) twice a day on days 1 to 14, and intravenous oxaliplatin at 130 mg/m2 on day 1. Thirty-two patients were enrolled onto this phase II study. By intention-to-treat analyses, eight patients (25%) experienced a partial response and 14 patients (44%) had stable disease for at least 12 weeks. The median progression-free survival was 5.4 months and the median overall survival was 14.7 months. These results were essentially unchanged when limited to the cohort of patients (78%) who received prior irinotecan for metastatic colorectal cancer. Most common grade 3 to 4 toxicities included diarrhea (38%), nausea/emesis (19%), fatigue (16%), dehydration (16%), and dermatitis (13%); grade 3 or 4 toxicities were reduced with a lower starting dose ...Continue Reading

References

Jul 1, 1995·Critical Reviews in Oncology/hematology·D S SalomonN Normanno
May 15, 2001·Endocrine-related Cancer·J Mendelsohn
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Jan 5, 2002·Expert Opinion on Investigational Drugs·R Midgley, D Kerr
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V Craig Jordan, Monica Morrow
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus M BornerArnaud D Roth
Oct 22, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnUNKNOWN American Society for Blood and Marrow Transplantation (ASBMT)
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Nov 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy Whelan, Mark Levine
Jan 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott M Lippman, Bernard Levin
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer
Apr 28, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H P KalofonosG Fountzilas
May 14, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C J A Punt
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Dell'Italia Meridionale
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy KuoBranimir I Sikic

❮ Previous
Next ❯

Citations

Jan 12, 2007·Cancer Chemotherapy and Pharmacology·Jeffrey A MeyerhardtCharles S Fuchs
Jun 15, 2007·Diseases of the Colon and Rectum·Michael J Overman, Paulo M Hoff
May 8, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A MeyerhardtD P Ryan
Aug 13, 2011·Japanese Journal of Clinical Oncology·Kammei RaiToshio Sato
Dec 17, 2008·Molecular Cancer Therapeutics·Elaine T LamLia Gore
Nov 15, 2006·Annals of Surgical Oncology·Neeltje SteeghsHans Gelderblom
Mar 26, 2011·Pathology Research International·Kevin M Sullivan, Peter S Kozuch
Oct 10, 2006·Future Oncology·Danish MazharWolfgang Heller
Jan 23, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J de Castro-CarpeñoM González Barón
Oct 22, 2008·Cancer Chemotherapy and Pharmacology·Emilio BajettaMargherita Galassi
Apr 3, 2009·Journal of Cancer Research and Clinical Oncology·Michael PohlA Reinacher-Schick
Jul 14, 2007·Expert Review of Anticancer Therapy·Jaume CapdevilaJosep Tabernero
Jan 1, 2009·Expert Review of Clinical Pharmacology·Rachel E Sanborn, Angela M Davies
Feb 17, 2007·Expert Opinion on Investigational Drugs·Joaquina Baranda, Stephen Williamson
Jul 28, 2015·Expert Opinion on Investigational Drugs·Yeh Chen LeeJohn R Zalcberg
Dec 18, 2013·Seminars in Diagnostic Pathology·Andrew M Bellizzi
Nov 28, 2007·Clinical Colorectal Cancer·Cristina GrávalosEsther Holgado
May 25, 2007·Surgical Oncology·Claire Kelly, Jim Cassidy
Sep 18, 2015·Drugs·Sameh Mikhail, Tanios Bekaii-Saab
Nov 4, 2008·Critical Reviews in Oncology/hematology·Jaume CapdevilaJosep Tabernero
Sep 1, 2016·Expert Opinion on Emerging Drugs·Ignacio MatosJosep Tabernero
Sep 4, 2012·The American Journal of Cardiology·Andrew P AmbrosyRonald M Witteles
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anirban P MitraRichard J Cote
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alain J GelibterRoberto Labianca
Oct 31, 2008·ANZ Journal of Surgery·Lie S ChanChristopher Christophi
Dec 21, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Amit MahipalShilpa Gupta
Apr 4, 2021·Cancers·Claudia CorròThibaud Koessler
Jun 8, 2021·Current Treatment Options in Oncology·Jianxia LiYanhong Deng
Jun 8, 2011·Seminars in Radiation Oncology·Brian G Czito, Christopher G Willett

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mace L RothenbergRobert J Coffey
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Jeffrey A MeyerhardtDavid P Ryan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Timothy KuoBranimir I Sikic
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Wells A MessersmithManuel Hidalgo
© 2022 Meta ULC. All rights reserved